EUCTR2017-004043-21-FR进行中（未招募）1 期
An exploratory, single centre, open label, pilot study investigating the efficacy and safety of OBE2109 200 mg daily For 12 weeks followed by 100 mg daily for 12 weeks in rectovaginal endometriosis.
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- ObsEva SA
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. The subject must provide written informed consent prior to initiation of any study related procedures.
- •2. The subject must be a pre-menopausal woman aged between 18 and 48 years inclusive at screening.
- •3. The subject must have history of regular menstrual cycles every 21-35 days and without intermenstrual bleeding heavier than spotting or staining.
- •4. The subject has Follicle-Stimulating Hormone (FSH) level = 20 IU/L at screening.
- •5. The subject has endometriosis with presence of a rectovaginal node (type II or III) of at least 2 cm at vaginal examination confirmed on MRI, and:
- •· Moderate to severe scoring on the mB&B scale for two out of the three subject assessed symptoms
- •(dysmenorrhea, non-menstrual pelvic pain and dyspareunia), and
- •· Pain during vaginal examination.
- •6. The subject has a Body Mass Index (BMI) =18 and =35 kg/m².
- •7. If of childbearing potential, the subject agrees to use one of the following birth control methods during the entire length of the treatment period of the study:
- •a. Sexual abstinence from heterosexual intercourse if routinely and consistently practised
- •b. Partner with vasectomy performed at least 6 months prior to the screening visit and with confirmed azoospermia
- •c. Double non-hormonal barrier contraception such as condom or diaphragm each combined with
- •spermicide.
- •8. If of non-childbearing potential, the subject must have had tubal ligation sterilisation at least two months before the screening visit.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 9
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. The subject has an abnormal endometrial biopsy within 6 months prior to starting study treatment (atypical hyperplasia, endometritis, polyps or carcinoma).
- •2. The subject has endometrioma with a diameter >3cm.
- •3. The subject has a previous bowel (rectal or sigmoid) resection.
- •4. The subject has had surgery for deep endometriosis in the 6 months preceding the screening visit.
- •5. The subject has had breast examination findings requiring intervention within the 6 months preceding the screening visit.
- •6. The subject has or has had an active pelvic infection within 1 month preceding the screening visit.
- •7. The subject is using an intrauterine device (IUD) or has used an IUD within the 3 months preceding the screening visit.
- •8. The subject is likely to require treatment during the study OR received treatment within a specified period prior to the screening visit with any of the medications listed below:
- •Gonadotropin releasing hormone (GnRH) antagonists 3 months
- •GnRH agonist injections/3-month depot injections 3 months/6 months
- •Oral contraceptives and other sex hormones 1 month
- •Depot contraceptives 6 months
- •Selective Progesterone Receptor Modulators (SPRMs)
- •Selective Estrogen Receptor Modulators (SERMs) 3 months
- •Systemic glucocorticoid treatments for acute diseases (not depot) 1 month
- •9. The subject is using or anticipates to use any of the following drugs: anticoagulants, aminocaproic acid, or any other medications that affect menstrual bleeding such as tranexamic acid.
- •10. The subject is pregnant or breast-feeding or is planning a pregnancy within the duration of the treatment period of the study.
- •11. The subject has history of known failed treatment with GnRH agonists or GnRH antagonists.
- •12. The subject has history of or current systemic glucocorticoid therapy for treatment of chronic diseases (e.g. Systemic Lupus Erythematosus (SLE), rheumatic arthritis).
- •13. The subject has history of, or known osteoporosis or other metabolic bone disease.
- •14. The subject has alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT) or total bilirubin = 2 times the upper limit of normal.
- •15. The subject has known positive HIV or viral hepatitis serology.
- •16. The subject has any known condition, including findings in the medical history or in the screening
- •assessments which, in the opinion of the investigator, constitutes a risk or a contraindication to the
- •participation of the subject in the trial or that could interfere with the trial objectives, conduct or evaluation.
- •17. The subject has history of (within twelve months prior to the screening visit), or known current problems with alcohol or drug abuse (including painkiller abuse).
- •18. The subject has any condition rendering her unable to understand the nature, scope and possible
- •consequences of the study, and/or evidence of an uncooperative attitude.
- •19. The subject has been administered any experimental drug in the 12 weeks before start of study treatment.
研究者
相似试验
进行中（未招募）
1 期
A pilot study to assess the efficacy and safety of OBE2109 in subjects with uterine adenomyosis.EUCTR2017-004042-14-FRObsEva SA9
进行中（未招募）
1 期
A prospective single centre, open label, pilot study to evaluate the safety of ICXP007 plus standard of care, for the treatment of lower extremity chronic, neuropathic diabetic foot ulcers - DFU IDiabetic foot ulcersEUCTR2006-000692-15-GBIntercytex15
已完成
1 期
Reducing symptoms in acute Acute Heart Failure with a man made vessel dilator peptideAcute Decompensated Congestive Heart Failure (ADCHF)Cardiovascular - Other cardiovascular diseasesRespiratory - Other respiratory disorders / diseasesACTRN12609000998246Madeleine Pharmaceuticals36
招募中
不适用
A Single-Center, Single-arm, Open-label, Exploratory Study to Evaluate the Efficacy and Safety of Intradermal Injection of Hyaluronic Acid FillerKCT0007664Hugel20
进行中（未招募）
不适用
Subcutaneous administration of Interleukin-2 prior to surgical intervention in case of sonographically and cytologically involved sentinel nodeThe trial is planned in a neo-adjuvant setting for a 4-weeks period in Melanoma patients with stage III. The stage is to be discovered by ultrasound and veriefied by fine needle punctere and cytology.EUCTR2011-001474-25-DEKlinik für Dermatologie, Venerologie und Allergologie; Charité - Universitätsmedizin Berlin20